Over the next five years of this Program Project we will continue to make strong efforts to bring together in a coordinated unit the clinical research disciplines and related laboratories of the Mayo Clinic for the purpose of improving both palliative and curative treatment of human gastrointestinal cancer. The following specific areas will be addressed: 1) Treatment of colorectal cancer. 2) Treatment of the less common gastrointestinal carcinomas and 3) Gastrointestinal Cancer Laboratory Science. We continue to place special emphasis on the development and testing of innovative approaches to regional disease and surgical adjuvant therapy with cure as a specific end point. Of primary importance will be the integration directly into clinical research programs of sophisticated laboratory endeavors in cancer pharmacology, cytogenetics and immunology. We will continue to utilize the particular strengths of this program which include an unexcelled depth of experience in gastrointestinal clinical cancer research; a devoted clinical research team including all concerned disciplines; the exceptionally large cancer patient population available at the Mayo Clinic permitting meaningful studies to be performed in a timely fashion; the uniquely large population of newly diagnosed gastrointestinal cancer permitting conduct of early disease studies; an extraordinarily large population of patients with less common cancers; strong relationships with community clinics in our region through the North Central Cancer Treatment Group permitting a continuum of management and expanded Phase III trials utilizing the same data base; a well developed Mayo Cancer Center Statistical Unit which is involved in all phases of our studies to insure sound protocol design, consistent data quality, and informed and objective data analysis; and ready availability of large amount of tissue and laboratory materials for basic laboratory study. We believe these ingredients combined with our established productivity and our documented accomplishment during the first two and one-half years of this grant provide maximum confidence that the work proposed will meet highest scientific standards and will be conducted with unexcelled quality and cost effectiveness.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA031224-06S1
Application #
3093408
Study Section
Cancer Therapeutics Program Project Review Committee (CTR)
Project Start
1984-03-01
Project End
1991-09-30
Budget Start
1991-09-02
Budget End
1991-09-30
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Goldberg, R M; Fleming, T R; Tangen, C M et al. (1998) Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 129:27-35
Suzuki, K; Dozois, R R; Devine, R M et al. (1996) Curative reoperations for locally recurrent rectal cancer. Dis Colon Rectum 39:730-6
Gilbert, J A; Bates, L A; Ames, M M (1995) Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors. Biochem Pharmacol 50:845-50
Martenson Jr, J A; Urias, R; Smalley, S R et al. (1995) Radiation therapy quality control in a clinical trial of adjuvant postoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys 32:51-5
Suzuki, K; Gunderson, L L; Devine, R M et al. (1995) Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer 75:939-52
Moertel, C G; Fleming, T R; Macdonald, J S et al. (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13:2936-43
Moertel, C G; Fleming, T R; Macdonald, J S et al. (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321-6
O'Connell, M J; Martenson, J A; Wieand, H S et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-7
Moertel, C G; Gunderson, L L; Mailliard, J A et al. (1994) Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol 12:21-7
Kardinal, C G; Moertel, C G; Wieand, H S et al. (1993) Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 71:2187-90

Showing the most recent 10 out of 49 publications